한독

002390KOSPI의약품 제조업

43.0 / 100

Reference Date: 2026-04-13

Financial Score15.0 / 40

News Sentiment13.0 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 2.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Han Dong, established in 1954, operates in pharmaceuticals, medical devices, health functional foods, and real estate leasing. Key products include Amaryl, Tenelria, and RediQ, with headquarters in Seoul's Gangnam-gu, a factory in Yongcheon, Chungcheongbuk, and a research institute in Gangseo-gu, Seoul. The company operates across multiple business segments.

Number of Employees

951people

Average Salary

78.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

0.51Industry Average 1.047.0Point

Half of industry avg (excellent)

ROE

-0.79Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

34.98Industry Average 11.980.0Point

2.9x industry avg (risky)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲207.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -8.5% (improving, 3yr)

Detailed News Sentiment

12 totalPositive 0Neutral 9Negative 0Average Sentiment Score 52.8

Neutral
햇빛·공기로 약 만든다 外 [과학게시판]
KAIST 연구팀이 빛과 공기로 의약품 원료를 생산하는 친환경 촉매 기술을 개발했다는 뉴스로, 한독과는 직접적인 관련이 없습니다.
Neutral
한독, 서울시의사회와 제57회 사랑의 금십자상 시상
한독은 서울시의사회와 '제57회 사랑의 금십자상' 시상식을 개최하여 언론인 4명에게 상을 수여했습니다.
Neutral
한독, 고인슐린증 치료제 임상 3상 재도전

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 10,410Won52-week high 12,40052-week low 10,020

1-month return2.0Point

1m -2.16% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
Neutral정기주주총회결과2026-03-26
Neutral사업보고서 (2025.12)2026-03-18